SSPC, Research Ireland Centre for Pharmaceuticals

Background

SSPC, the Research Ireland Centre for Pharmaceuticals, is a leading interdisciplinary research hub dedicated to advancing the pharmaceutical and biopharmaceutical industries. Hosted at the University of Limerick, Ireland, SSPC collaborates with nine other Irish research-performing organizations, including University College Cork, University of Galway, Trinity College Dublin, Royal College of Surgeons Ireland, Dublin City University, University College Dublin, Maynooth University, and NIBRT - National Institute for Bioprocessing Research and Training.

Established in 2007, SSPC has grown into a globally recognized center of excellence, focusing on the entire pharmaceutical production chain—from molecule synthesis to the formulation of medicines. Its mission is to deliver industry-relevant technical solutions that result in job growth and retention within the sector in Ireland and to enhance the skills base of qualified scientists and engineers.

Key Strategic Focus

SSPC's strategic focus encompasses several core objectives:

• Research Excellence: Conducting cutting-edge research across the pharmaceutical production chain, including molecule synthesis, material isolation, and drug formulation.

• Industry Collaboration: Engaging in impactful partnerships with over 50 industry partners, ranging from small enterprises to multinational corporations, to address key challenges in the pharmaceutical sector.

• Talent Development: Nurturing a pipeline of highly skilled scientists and engineers through PhD training programs and various continuous professional development mechanisms, with a notable 70% transition rate of SSPC researchers to industry roles globally.

• Global Impact: Fostering international collaborations and contributing to the global advancement of pharmaceutical sciences.

Financials and Funding

Since its inception, SSPC has secured substantial funding, including:

• Initial Funding: €6 million from Research Ireland in 2007.

• Phase II Funding: €61 million in 2018, supporting 68 investigators and over 100 PhD students.

• Economic Impact: Over €1.3 billion in economic impact since 2008, with a 26-fold return on core investment, generating €5.27 for the Irish economy for every €1 of public and industry funding received.

Pipeline Development

SSPC's research spans the entire pharmaceutical production chain, focusing on:

• Molecule Synthesis: Developing new methodologies for the asymmetric synthesis of active pharmaceutical ingredients (APIs) and future drug candidates.

• Material Science: Advancing the understanding of single-component crystalline materials (SCCMs) and multi-component crystalline materials (MCCMs) to enable improved orally delivered drug products.

• Drug Formulation: Optimizing the development, production, and use of safe and effective medicines, with a particular emphasis on poorly soluble drugs and personalized medicine.

• Manufacturing Processes: Implementing continuous manufacturing, flow chemistry, and end-to-end manufacturing methodologies to enable disruptive changes in drug substance and product manufacturing.

• Modelling and Simulation: Developing new techniques to design and predict behavior in silico, reducing trial-and-error experimentation and advancing process modeling, process analytical technology (PAT), and statistical modeling for model predictive control of pharmaceutical manufacturing.

Technological Platform and Innovation

SSPC employs several proprietary technologies and scientific methodologies, including:

• Flow Chemistry: Design and implementation of continuous manufacturing processes to enhance efficiency and scalability.

• Asymmetric Synthesis: Development of new methodologies for the asymmetric synthesis of APIs and future drug candidates.

• Crystallization Techniques: Advancements in pharmaceutical crystallization to improve drug purity and bioavailability.

• Amorphous Materials: Research into amorphous materials to enhance drug solubility and stability.

• Process Analytical Technology (PAT): Integration of PAT tools for real-time monitoring and control of manufacturing processes.

• Computational Modeling: Utilization of in silico modeling to predict drug behavior and optimize formulations.

Leadership Team

SSPC is led by a team of distinguished professionals:

• Professor Damien Thompson: Scientific Director, leading the strategic direction and research initiatives of SSPC.

• Dr. Sarah Hayes: Chief Operating Officer, overseeing the operational aspects and ensuring the effective implementation of SSPC's programs.

• Aisling O'Hehir: Education and Public Engagement Manager, responsible for fostering relationships with educational institutions and managing public engagement activities.

• Jamie Guidera: Business Development and Commercialisation Manager, focusing on industry partnerships and the commercialization of research outputs.

Market Insights and Competitor Profile

The global pharmaceutical industry is experiencing significant growth, driven by an aging population, increasing prevalence of chronic diseases, and advancements in biotechnology. Ireland's pharmaceutical sector is a key contributor to this growth, with a strong emphasis on research and development, manufacturing excellence, and a skilled workforce.

Key competitors in the pharmaceutical research and development sector include:

• Trinity College Dublin's School of Pharmacy and Pharmaceutical Sciences: Collaborates with SSPC on the Centre for Doctoral Training in Transformative Pharmaceutical Technologies.

• National Institute for Bioprocessing Research and Training (NIBRT): Partners with SSPC in advancing biopharmaceutical research and training.

• University College Cork: Collaborates with SSPC on various research initiatives and PhD training programs.

Strategic Collaborations and Partnerships

SSPC has established numerous collaborations with industry leaders, including:

• Pfizer: Engages in research projects to enhance pharmaceutical manufacturing processes.

• Eli Lilly: Collaborates on the development of advanced drug delivery systems.

• Janssen: Partners in research to improve drug formulation and manufacturing techniques.

• MSD: Works together to address challenges in biologics manufacturing.

• Sanofi: Collaborates on projects focusing on sustainable pharmaceutical production.

These strategic collaborations enhance SSPC's research capabilities, foster innovation, and contribute to the advancement of pharmaceutical sciences. The organization’s emphasis on talent development ensures a continuous pipeline of skilled professionals, strengthening Ireland's position in the global pharmaceutical market.

Strategic Opportunities and Future Directions

SSPC is well-positioned to capitalize on emerging trends in the pharmaceutical industry, including:

• Biopharmaceuticals: Expanding research into biologics and biosimilars to meet growing global demand.

• Personalized Medicine: Developing tailored drug formulations to address individual patient needs.

• Sustainable Manufacturing: Implementing green technologies to reduce the environmental impact of pharmaceutical production.

• Digitalization: Leveraging data analytics and artificial intelligence to optimize drug development and manufacturing processes.

Social Media Presence

SSPC maintains an active presence on multiple social media platforms to engage with the scientific community and the public:

• Twitter: @SSPCPharma

• LinkedIn: SSPC Research Ireland Centre for Pharmaceuticals

• Facebook: SSPC Research Ireland Centre for Pharmaceuticals